The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology
Open accessAbstract
This selection from the NCCN Guidelines for Merkel Cell Carcinoma (MCC) focuses on areas impacted by recently emerging data, including sections describing MCC risk factors, diagnosis, workup, follow-up, and management of advanced disease with radiation and systemic therapy. Included in these sections are discussion of the new recommendations for use of Merkel cell polyomavirus as a biomarker and new recommendations for use of checkpoint immunotherapies to treat metastatic or unresectable disease. The next update of the complete version of the NCCN Guidelines for MCC will include more detailed information about elements of pathology and addresses additional aspects of management of MCC, including surgical management of the primary tumor and draining nodal basin, radiation therapy as primary treatment, and management of recurrence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Clonal Integration of a Polyomavirus in Human Merkel Cell Carcinoma
Feng, H., Shuda, M., Chang, Y., & Moore, P. S. (2008) · Science · doi:10.1126/science.1152586 · Cited by 3,208
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258
Self-citationKaufman, H. L., Russell, J., Hamid, O., Bhatia, S., Terheyden, P., D'Angelo, S. P., Shih, K. C., Lebbé, C., Linette, G. P., Milella, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30364-3 · Cited by 1,236
Self-citationClinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features
Heath, M., Jaimes, N., Lemos, B., Mostaghimi, A., Wang, L. C., Peñas, P. F., & Nghiem, P. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.11.020 · Cited by 934
Self-citationPatnaik, A., Kang, S. P., Rasco, D., Papadopoulos, K. P., Elassaiss-Schaap, J., Beeram, M., Drengler, R., Chen, C., Smith, L., Espino, G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2607 · Cited by 807
Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies.
Moll, R., Löwe, A., Laufer, J., & Franke, W. W. (1992) · PubMed Central · Cited by 806
Merkel Cell Carcinoma: Prognosis and Treatment of Patients From a Single Institution
Allen, P. J., Bowne, W. B., Jaques, D. P., Brennan, M. F., Busam, K., & Coit, D. G. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.329 · Cited by 739
Epidemiology of primary Merkel cell carcinoma in the United States
Agelli, M., & Clegg, L. X. (2003) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(03)02108-x · Cited by 568
Lemos, B. D., Storer, B. E., Iyer, J. G., Phillips, J. L., Bichakjian, C. K., Fang, L. C., Johnson, T. M., Liegeois-Kwon, N. J., Otley, C. C., Paulson, K. G., et al. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.02.056 · Cited by 559
Self-citation
Cited by
Nghiem, P., Bhatia, S., Lipson, E. J., Sharfman, W. H., Kudchadkar, R. R., Brohl, A. S., Friedlander, P. A., Daud, A., Kluger, H. M., Reddy, S. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01896 · Cited by 396
Self-citationKaufman, H. L., Russell, J. S., Hamid, O., Bhatia, S., Terheyden, P., D’Angelo, S. P., Shih, K. C., Lebbé, C., Milella, M., Brownell, I., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0310-x · Cited by 334
Hasan, N., Nadaf, A., Imran, M., Jiba, U., Sheikh, A., Almalki, W. H., Almujri, S. S., Mohammed, Y. H., Kesharwani, P., & Ahmad, F. J. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01854-3 · Cited by 322
Product review: Avelumab, an anti-PD-L1 antibody
Collins, J. M., & Gulley, J. L. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2018.1551671 · Cited by 91
Merkel cell carcinoma: an updated review focused on bone and bone marrow metastases
Scotti, B., Broseghini, E., Ricci, C., Corti, B., Viola, C., Misciali, C., Baraldi, C., Vaccari, S., Lambertini, M., Venturi, F., et al. (2025) · Cancers · doi:10.3390/cancers17132253 · Cited by 9
Metadata
- Authors
- Bichakjian, C. K., Olencki, T., Aasi, S. Z., Alam, M., Andersen, J. S., Blitzblau, R., Bowen, G. M., Contreras, C. M., Daniels, G. A., Decker, R., Farma, J. M., Fisher, K., Gastman, B., Ghosh, K., Grekin, R. C., Grossman, K., Ho, A. L., Lewis, K. D., Loss, M., Lydiatt, D. D., Messina, J., Nehal, K. S., Nghiem, P., Puzanov, I., Schmults, C. D., Shaha, A. R., Thomas, V., Xu, Y. G., Zic, J. A., Hoffmann, K. G., & Engh, A. M.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2018-06
- Volume
- 16
- Issue
- 6
- Pages
- 742-774
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W2808507967
- Cited by
- 319
- References
- 116
- FWCI
- 14.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. https://app.cochat.ai/papers/10.6004/jnccn.2018.0055
- The paper
- Bichakjian, C. K., Olencki, T., Aasi, S. Z., Alam, M., Andersen, J. S., Blitzblau, R., Bowen, G. M., Contreras, C. M., Daniels, G. A., Decker, R., Farma, J. M., Fisher, K., Gastman, B., Ghosh, K., Grekin, R. C., Grossman, K., Ho, A. L., Lewis, K. D., Loss, M., . . . Engh, A. M. (2018). Merkel Cell Carcinoma, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2018.0055
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
